Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry Wagner

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Journal of Oncology Practice|July 19, 2015
Optimal Frequency of Psychosocial Distress Screening in Radiation OncologyClayton B Hess, Maria Singer, Aliasgher Khaku, et al.
Lung Cancer (Amsterdam, Netherlands)|September 27, 2003
Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancerSteven M Keller, Mark G Vangel, Henry Wagner, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 4, 2011
Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancerGerold Bepler, Thomas J Dilling, Henry Wagner, et al.
Cancer Control : Journal of the Moffitt Cancer Center|October 29, 2003
Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institutionGeorge R Simon, John C Ruckdeschel, Charles Williams, et al.
Cancer Biology & Therapy|December 2, 2016
Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab aloneKristian M Koller, Heath B Mackley, Jason Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2012
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancerArlene A Forastiere, Qiang Zhang, Randal S Weber, et al.
Neuro-Oncology|March 12, 2015
Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)Andrew B Lassman, Stephanie L Pugh, Mark R Gilbert, et al.
Gastrointestinal Cancer Research : GCR|January 8, 2013
Phase II Trial of Paclitaxel/Cisplatin Followed by Surgery and Adjuvant Radiation Therapy and 5-Fluorouracil/Leucovorin for Gastric Cancer (ECOG E7296)A Bapsi Chakravarthy, Paul J Catalano, Joshua K Mondschein, et al.
Clinical Lung Cancer|August 19, 2020
Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508)Jyoti D Patel, Ju-Whei Lee, David P Carbone, et al.
British Journal of Haematology|January 30, 2013
The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496Andrew M Evens, Fangxin Hong, Leo I Gordon, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Journal of Oncology Practice|July 19, 2015
Optimal Frequency of Psychosocial Distress Screening in Radiation OncologyClayton B Hess, Maria Singer, Aliasgher Khaku, et al.
Lung Cancer (Amsterdam, Netherlands)|September 27, 2003
Second primary tumors following adjuvant therapy of resected stages II and IIIa non-small cell lung cancerSteven M Keller, Mark G Vangel, Henry Wagner, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 4, 2011
Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancerGerold Bepler, Thomas J Dilling, Henry Wagner, et al.
Cancer Control : Journal of the Moffitt Cancer Center|October 29, 2003
Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institutionGeorge R Simon, John C Ruckdeschel, Charles Williams, et al.
Cancer Biology & Therapy|December 2, 2016
Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab aloneKristian M Koller, Heath B Mackley, Jason Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2012
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancerArlene A Forastiere, Qiang Zhang, Randal S Weber, et al.
Neuro-Oncology|March 12, 2015
Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)Andrew B Lassman, Stephanie L Pugh, Mark R Gilbert, et al.
Gastrointestinal Cancer Research : GCR|January 8, 2013
Phase II Trial of Paclitaxel/Cisplatin Followed by Surgery and Adjuvant Radiation Therapy and 5-Fluorouracil/Leucovorin for Gastric Cancer (ECOG E7296)A Bapsi Chakravarthy, Paul J Catalano, Joshua K Mondschein, et al.
Clinical Lung Cancer|August 19, 2020
Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508)Jyoti D Patel, Ju-Whei Lee, David P Carbone, et al.
British Journal of Haematology|January 30, 2013
The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496Andrew M Evens, Fangxin Hong, Leo I Gordon, et al.
Pageof 5